Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 6;17(9):1490.
doi: 10.3390/ijms17091490.

The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

Alberto Chisari  1 , Anna Maria Pistritto  2 , Raffaele Piccolo  3 , Alessio La Manna  4 , Gian Battista Danzi  5
Affiliations
Review

The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

Alberto Chisari et al. Int J Mol Sci. .

Abstract

The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials. Results from these two landmark studies suggested an excellent efficacy and safety profile of the Ultimaster DES across several lesion and patient subsets, with similar clinical outcomes to contemporary, new-generation DES. The aim of this review is to summarize the rationale behind this novel DES technology and to provide an update of available evidence about the clinical performance of the Ultimaster DES.

Keywords: Ultimaster stent; biodegradable polymer drug eluting stent; coronary stent; new-generation DES; sirolimus-eluting stent.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Gradient coating of Ultimaster coronary stent: Gradient coating consists in the absence of drug polymer on the hinges of the stent in order to reduce the risk of polymer damage that can occur with circumferential coating. The gradient coating is achieved by the multi-layer coating process, protected by Terumo’s patents.
Figure 2
Figure 2
Process of polymer degradation after stent implantation: Bioresorbable polymer is metabolized into carbon dioxide and water and excreted via urine and feces within 3–4 months. Sirolimus is released along with polymer bioabsorption. After that time the Ultimaster drug-eluting stent is expected to behave as a thin strut bare metal stent. Blue spots indicate % drug release over time; red circles indicate % amount of polymer remaining on stent surface.
See this image and copyright information in PMC

References

    1. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O’Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003;349:1315–1323. doi: 10.1056/NEJMoa035071. - DOI - PubMed
    1. Stone G.W., Lansky A.J., Pocock S.J., Gersh B.J., Dangas G., Wong S.C., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med. 2009;360:1946–1959. doi: 10.1056/NEJMoa0810116. - DOI - PubMed
    1. Jeremias A., Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann. Intern. Med. 2008;148:234–238. doi: 10.7326/0003-4819-148-3-200802050-00199. - DOI - PubMed
    1. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., Pfisterer M.E., Stone G.W., Leon M.B., de Lezo J.S., et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet. 2007;370:937–948. doi: 10.1016/S0140-6736(07)61444-5. - DOI - PubMed
    1. Camenzind E., Steg P.G., Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation. 2007;115:1440–1455. doi: 10.1161/CIRCULATIONAHA.106.666800. - DOI - PubMed

MeSH terms

LinkOut - more resources